A genetic off‐target event in a site‐specific integration cell line expressing monoclonal antibody has no impact on commercial suitability
Biotechnology Progress · 2023
DOI: 10.1002/btpr.3320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2023. Verfasst von Barbara Tevelev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Site‐specific integration (SSI) cell line systems are gaining popularity for biotherapeutic development and production. Despite the proven advantages for these expression hosts, the SSI system is still susceptible to rare off‐target events and potential vector rearrangements. Here we describe the development process of an SSI cell line for production of an IgG1 monoclonal antibody (mAb‐086). During cell line generational studies to assess suitability of clone C10 for commercial purposes, restriction fragment lengths of genomic DNA harboring the light chain (LC) were not in agreement with the predicted size. We first confirmed that the SSI landing‐pad achieved occupancy of the desired expression plasmid. Additional investigation revealed that random integration had occurred, resulting in the acquisition of a partial copy of the LC and a full‐length copy of the heavy chain (HC) at a different locus in the host genome. This off‐target event had no impact on the genotypic consistency and phenotypic stability of the cell line, the production process, or the drug substance product quality. Given the genetic, phenotypic, and process consistency of the cell line, clone C10 was deemed suitable as a manufacturing cell line.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri, USA.
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, USA.
ORCID-Profile: Barbara Tevelev, John J Scarcelli
Förderung
- Pfizer
Zitieren
APA
Tevelev, B., Chambers, A., Ghosh, S., Zhang, Y., Marzili, L., Rouse, J. C., Han, S., Moffat, M., & Scarcelli, J. J. (2023). A genetic off‐target event in a site‐specific integration cell line expressing monoclonal antibody has no impact on commercial suitability. Biotechnology Progress. https://doi.org/10.1002/btpr.3320
Vancouver
Tevelev B, Chambers A, Ghosh S, Zhang Y, Marzili L, Rouse JC, et al. A genetic off‐target event in a site‐specific integration cell line expressing monoclonal antibody has no impact on commercial suitability. Biotechnology Progress. 2023. doi:10.1002/btpr.3320
BibTeX
@article{Tevelev2023,
author = {Tevelev, Barbara and Chambers, Andre and Ghosh, Swap and Zhang, Ying and Marzili, Lisa and Rouse, Jason C and Han, Shu and Moffat, Mark and Scarcelli, John J},
title = {A genetic off‐target event in a site‐specific integration cell line expressing monoclonal antibody has no impact on commercial suitability},
journal = {Biotechnology Progress},
year = {2023},
doi = {10.1002/btpr.3320}
}
EUVIMED